Clinical trialUNITERAREApr 30
New Recruiting Trial: A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravis (gMG)
Researchers are testing a new medicine called inebilizumab in children who have generalized myasthenia gravis (gMG), a rare condition where the immune system attacks muscles and causes weakness. This study will check how the medicine works in children's bodies, whether it's safe, and what side effects it might cause. The study is now accepting patients and is expected to start in April 2026.
WHY IT MATTERSThis is the first trial testing inebilizumab specifically in children with gMG—previous studies only included adults—so it could lead to the first approved treatment option for this age group.